Valley Fever Awareness and Vaccine Development and Manufacturing Act of 2024
The source supplies the latest action, but no lifecycle stage.
Latest action (8 Oct 2024): Referred to the House Committee on Energy and Commerce.
What this bill does
H.R. 9942, the Valley Fever Awareness and Vaccine Development and Manufacturing Act of 2024, directs the Secretary of Health and Human Services to coordinate a government-wide effort to support development, licensing, and initial manufacturing of a human vaccine for valley fever (coccidioidomycosis), a fungal disease. It requires appointment of a Vaccine Coordinator from the FDA or NIH, who would issue periodic public reports, convene meetings with agencies and outside experts, and help produce a national strategy—including a timeline aiming for a licensed, manufactured vaccine by January 1, 2034. The bill also directs NIH, FDA, and CDC to issue guidance on vaccine development, manufacturing, and approval, and authorizes grant and contract programs (with specified grant-size ranges) to support vaccine development and manufacturing. It further creates a National Valley Fever Registry at CDC, overseen by a newly established advisory committee, to collect data on valley fever and related fungal diseases, and authorizes related grants once a required committee report is submitted.
The bill would primarily affect federal health agencies (HHS, NIH, FDA, CDC, BARDA), researchers, vaccine manufacturers, academic and nonprofit entities eligible for grants, and patients/communities affected by valley fever, particularly in regions where the disease is prevalent. It authorizes specific funding levels for fiscal years 2025–2030 (and 2026) to carry out these activities.
The bill was introduced October 8, 2024, by Rep. John Duarte with several cosponsors, referred to the House Committee on Energy and Commerce, and did not receive a vote before the end of the 118th Congress. It would need to be reintroduced in a future Congress to be considered further.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
8 Oct 2024
Referred to the House Committee on Energy and Commerce.
Common questions
- What does H.R. 9942 do?
- H.R. 9942, the Valley Fever Awareness and Vaccine Development and Manufacturing Act of 2024, directs the Secretary of Health and Human Services to coordinate a government-wide effort to support development, licensing, and initial manufacturing of a human vaccine for valley fever (coccidioidomycosis), a fungal disease. It requires appointment of a Vaccine Coordinator from the FDA or NIH, who would issue periodic public reports, convene meetings with agencies and outside experts, and help produce a national strategy—including a timeline aiming for a licensed, manufactured vaccine by January 1, 2034. The bill also directs NIH, FDA, and CDC to issue guidance on vaccine development, manufacturing, and approval, and authorizes grant and contract programs (with specified grant-size ranges) to support vaccine development and manufacturing. It further creates a National Valley Fever Registry at CDC, overseen by a newly established advisory committee, to collect data on valley fever and related fungal diseases, and authorizes related grants once a required committee report is submitted. The bill would primarily affect federal health agencies (HHS, NIH, FDA, CDC, BARDA), researchers, vaccine manufacturers, academic and nonprofit entities eligible for grants, and patients/communities affected by valley fever, particularly in regions where the disease is prevalent. It authorizes specific funding levels for fiscal years 2025–2030 (and 2026) to carry out these activities. The bill was introduced October 8, 2024, by Rep. John Duarte with several cosponsors, referred to the House Committee on Energy and Commerce, and did not receive a vote before the end of the 118th Congress. It would need to be reintroduced in a future Congress to be considered further.
- Has H.R. 9942 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 9942. Check the latest action and official source below.
- Who sponsored H.R. 9942?
- H.R. 9942 was sponsored by Rep. Duarte, John S. [R-CA-13] (R-CA), with 6 cosponsors.
- What's the latest action on H.R. 9942?
- Referred to the House Committee on Energy and Commerce. (8 Oct 2024).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Duarte, John S. [R-CA-13]
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.